Cargando…
Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats
Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/ https://www.ncbi.nlm.nih.gov/pubmed/37456557 http://dx.doi.org/10.1016/j.crpvbd.2023.100126 |
_version_ | 1785072906596777984 |
---|---|
author | Mencke, Norbert Bäumer, Wolfgang Fraatz, Kristine Krebber, Ralph Schneider, Marc Blazejak, Katrin |
author_facet | Mencke, Norbert Bäumer, Wolfgang Fraatz, Kristine Krebber, Ralph Schneider, Marc Blazejak, Katrin |
author_sort | Mencke, Norbert |
collection | PubMed |
description | Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ml/kg to cats, tigolaner reached mean peak concentrations of 1352 μg/l with a T(max) of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 l/kg and plasma clearance was low with 0.005 l/h/kg. Overall plasma exposure was 1566 mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 μg/l and 48 μg/l (reached after 1.5 days and 5 h, respectively). Overall plasma exposures were 20.6 and 3.69 mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks. |
format | Online Article Text |
id | pubmed-10344656 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103446562023-07-14 Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats Mencke, Norbert Bäumer, Wolfgang Fraatz, Kristine Krebber, Ralph Schneider, Marc Blazejak, Katrin Curr Res Parasitol Vector Borne Dis Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova Felpreva® for cats contains the new acaricidal/insecticidal active ingredient tigolaner in a fixed combination with the nematocidal and cestocidal compounds emodepside and praziquantel, respectively. The plasma pharmacokinetics of tigolaner, emodepside, and praziquantel were evaluated in clinically healthy cats following topical (spot-on) treatment as fixed combination Felpreva®. For the determination of bioavailability intravenous administration of single active ingredients was also performed. After a single topical administration of Felpreva® using the target dose volume of 0.148 ml/kg to cats, tigolaner reached mean peak concentrations of 1352 μg/l with a T(max) of 12 days and a mean half-life of 24 days. Simulation of repetitive topical administration every 91 days indicates only a low risk of accumulation after reaching steady state within two to three administrations. The volume of distribution calculated after intravenous dosing was 4 l/kg and plasma clearance was low with 0.005 l/h/kg. Overall plasma exposure was 1566 mg∗h/l after topical administration, providing an absolute bioavailability of 57%. Tigolaner was mainly cleared via the faeces (54% within 28 days), renal clearance was neglectable (< 0.5% within 28 days). Emodepside and praziquantel showed mean peak concentrations of 44 μg/l and 48 μg/l (reached after 1.5 days and 5 h, respectively). Overall plasma exposures were 20.6 and 3.69 mg∗h/l, respectively. The elimination half-life was 14.5 days for emodepside and 10 days for praziquantel after topical administration. After topical administration of Felpreva® using 2.5× and 5× dose multiples an almost proportional increase of plasma exposure was observed for all three active ingredients. With the addition of tigolaner, Felpreva® combines the established pharmacokinetic (PK) characteristics of emodepside and praziquantel contained in Profender® spot-on for cats with the favourable PK of tigolaner suitable for a 3-months protection against fleas and ticks. Elsevier 2023-06-22 /pmc/articles/PMC10344656/ /pubmed/37456557 http://dx.doi.org/10.1016/j.crpvbd.2023.100126 Text en © 2023 Vetoquinol S.A. Lure, France https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova Mencke, Norbert Bäumer, Wolfgang Fraatz, Kristine Krebber, Ralph Schneider, Marc Blazejak, Katrin Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title | Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title_full | Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title_fullStr | Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title_full_unstemmed | Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title_short | Plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (Felpreva®) and of intravenous administration of the individual active ingredients in cats |
title_sort | plasma pharmacokinetics of tigolaner, emodepside, and praziquantel following topical administration of a combination product (felpreva®) and of intravenous administration of the individual active ingredients in cats |
topic | Articles from the special issue on Felpreva®: A novel spot-on formulation containing tigolaner, emodepside and praziquantel for parasite control for cats, Edited by Drs Luis Cardoso and Aneta Kostadinova |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344656/ https://www.ncbi.nlm.nih.gov/pubmed/37456557 http://dx.doi.org/10.1016/j.crpvbd.2023.100126 |
work_keys_str_mv | AT menckenorbert plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats AT baumerwolfgang plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats AT fraatzkristine plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats AT krebberralph plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats AT schneidermarc plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats AT blazejakkatrin plasmapharmacokineticsoftigolaneremodepsideandpraziquantelfollowingtopicaladministrationofacombinationproductfelprevaandofintravenousadministrationoftheindividualactiveingredientsincats |